Analyst Price Targets — TXG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 1, 2026 6:13 am | Dan Leonard | RBC Capital | $70.00 | $62.45 | StreetInsider | RBC Capital Starts 10X Genomics (TXG) at Sector Perform |
| August 12, 2026 1:09 pm | Mason Carrico | Stephens | $65.00 | $58.34 | TheFly | 10x Genomics price target raised to $65 from $50 at Stephens |
| August 10, 2026 11:18 am | — | Piper Sandler | $47.00 | $52.03 | TheFly | 10x Genomics price target raised to $47 from $42 at Piper Sandler |
| August 10, 2026 9:19 am | Kyle Mikson | Canaccord Genuity | $60.00 | $52.03 | StreetInsider | 10X Genomics (TXG) PT Raised to $60 at Canaccord |
| August 7, 2026 1:24 pm | — | Morgan Stanley | $40.00 | $48.32 | TheFly | 10x Genomics price target raised to $40 from $37 at Morgan Stanley |
| August 7, 2026 1:04 pm | — | Stifel Nicolaus | $50.00 | $47.15 | TheFly | 10x Genomics price target raised to $50 from $25 at Stifel |
| July 17, 2026 12:45 pm | — | Leerink Partners | $40.00 | $44.12 | TheFly | 10x Genomics price target raised to $40 from $23 at Leerink |
| July 14, 2026 10:55 am | Kyle Mikson | Canaccord Genuity | $50.00 | $41.77 | TheFly | 10x Genomics price target raised to $50 from $32 at Canaccord |
| July 9, 2026 10:56 am | Kallum Titchmarsh | Morgan Stanley | $37.00 | $37.47 | TheFly | 10x Genomics price target raised to $37 from $22 at Morgan Stanley |
| June 24, 2026 8:49 am | Luke Sergott | Barclays | $40.00 | $31.87 | TheFly | 10x Genomics price target raised to $40 from $30 at Barclays |
Latest News for TXG
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.
10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences PR Newswire PLEASANTON, Calif., Aug. 28, 2
Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TXG.
U.S. House Trading
No House trades found for TXG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.